ArticlePloS one2012
A cell cycle role for the epigenetic factor CTCF-L/BORIS.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Review
- Article
- Differentially CTCF-Binding Sites in Cattle Rumen Tissue during Weaning.International journal of molecular sciences · 2022Article
- The Contributions of Cancer-Testis and Developmental Genes to the Pathogenesis of Keratinocyte Carcinomas.Cancers · 2022Review
- BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.Cell death discovery · 2020Article
- Review
- Disruption of CTCF-YY1-dependent looping of the human papillomavirus genome activates differentiation-induced viral oncogene transcription.PLoS biology · 2018Article
- BORIS: a key regulator of cancer stemness.Cancer cell international · 2018Review
- Investigation of fusion gene expression in HCT116 cells.Oncology letters · 2017Article
- Aging as an Epigenetic Phenomenon.Current genomics · 2017Review
- The Role of p16International journal of molecular sciences · 2017Review
- FOXM1 allows human keratinocytes to bypass the oncogene-induced differentiation checkpoint in response to gain of MYC or loss of p53.Oncogene · 2017Article
- Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer.Scientific reports · 2017Article
- Reciprocal Regulation of the Cardiac Epigenome by Chromatin Structural Proteins Hmgb and Ctcf: IMPLICATIONS FOR TRANSCRIPTIONAL REGULATION.The Journal of biological chemistry · 2016Article
- Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.Oncogene · 2015Article
- Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.PloS one · 2015Article
- Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas - a pilot study.Pathology oncology research : POR · 2014Article
- Long range epigenetic silencing is a trans-species mechanism that results in cancer specific deregulation by overriding the chromatin domains of normal cells.Molecular oncology · 2013Article
- BORIS/CTCFL is an RNA-binding protein that associates with polysomes.BMC cell biology · 2013Article
- The role of chromatin insulators in nuclear architecture and genome function.Current opinion in genetics & development · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CTCF is a ubiquitous epigenetic regulator that has been proposed as a master keeper of chromatin organisation. CTCF-like, or BORIS, is thought to antagonise CTCF and has been found in normal testis, ovary and a large variety of tumour cells. The cellular function of BORIS remains intriguing although it might be involved in developmental reprogramming of gene expression patterns. We here unravel the expression of CTCF and BORIS proteins throughout human epidermis. While CTCF is widely distributed within the nucleus, BORIS is confined to the nucleolus and other euchromatin domains. Nascent RNA experiments in primary keratinocytes revealed that endogenous BORIS is present in active transcription sites. Interestingly, BORIS also localises to interphase centrosomes suggesting a role in the cell cycle. Blocking the cell cycle at S phase or mitosis, or causing DNA damage, produced a striking accumulation of BORIS. Consistently, ectopic expression of wild type or GFP- BORIS provoked a higher rate of S phase cells as well as genomic instability by mitosis failure. Furthermore, down-regulation of endogenous BORIS by specific shRNAs inhibited both RNA transcription and cell cycle progression. The results altogether suggest a role for BORIS in coordinating S phase events with mitosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.